Seeking to defend its growing proteomics patent portfolio, Invitrogen sued Bio-Rad Laboratories earlier this month claiming that some of its electrophoresis gels infringe upon certain Invitrogen patents, BioCommerce Week has learned.

The suit, filed on April 8 with the United States District Court of the Southern District of California, alleges that a number of Bio-Rad's Criterion XT gels infringe three patents owned by Invitrogen: U.S. Patent No. 5,922,185, No. 6,162,338, and No. 6,783,651.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.